Andere Sprachen Bristol-Myers Squibb Company BOERSE MUENCHEN

Aktien

850501

US1101221083

BRM

Realtime BOERSE MUENCHEN Andere Börsenplätze 09:01:07 17.06.2024			% 5 Tage	% 1. Jan.
38,6 ^EUR	-0,16 %		+0,80 %	-16,86 %

13.06.	Augtyro von Bristol-Myers Squibb erhält beschleunigte FDA-Zulassung zur Behandlung von soliden Tumoren	MT
13.06.	Bristol Myers Squibb gibt bekannt, dass die US-Arzneimittelbehörde FDA Augtyro (Repotrectinib) für die Behandlung von Patienten mit NTRK-positiven lokal fortgeschrittenen oder metastasierten soliden Tumoren genehmigt hat	CI

Andere Sprachen

Schalten Sie alle Nachrichten frei: Seien Sie als Erster informiert und reagieren Sie vor den Märkten!

100% kostenlose Registrierung

Bristol Myers : approbation de la FDA pour un traitement	14.06.
Bristol-Myers Squibb's Augtyro Gets FDA Accelerated Approval for Treatment of Solid Tumors	13.06.
Bristol Myers Squibb's Augtyro Gets FDA Accelerated Approval	13.06.
U.S. Food and Drug Administration Approves Augtyro™ (repotrectinib), a Next-Generation Tyrosine Kinase Inhibitor (TKI), for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13.06.
Bristol Myers Squibb Announces U.S. Food and Drug Administration Approves Augtyro (repotrectinib) for the Treatment of Patients with NTRK-Positive Locally Advanced or Metastatic Solid Tumors	13.06.
Evotec to Receive $20 Million Under Neuroscience Partnership with Bristol Myers Squibb	12.06.
Evotec Gets $20 Million Milestone Payment in Neurodegenerative Disease Collaboration With Bristol Myers Squibb	12.06.
Evotec Announces Progress in Neuroscience Collaboration with Bristol Myers Squibb	12.06.
ABL Bio, BMS Collaborate on Gastric Cancer Treatment Trial	10.06.
Geron shares surge after U.S. FDA approves blood disorder drug	07.06.
I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	05.06.
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma	05.06.
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	05.06.
Bristol-Myers Squibb Says Opdivo Plus Yervoy Therapy Improves Survival of Liver Cancer Patients	04.06.
Bristol Myers : résultats positifs dans le cancer du foie	04.06.
Bristol Myers Squibb Announces Opdivo (nivolumab) Plus Yervoy (ipilimumab) Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carcinoma in CheckMate -9DW Trial	04.06.
Bristol Myers Squibb Announces Opdivo Plus Yervoy Significantly Improved Overall Survival Compared to Lenvatinib or Sorafenib as First-Line Treatment for Patients with Advanced Hepatocellular Carinoma in Checkmate -9DW Trial	04.06.
Bristol Myers Squibb to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference	04.06.
Envisagenics, Inc. announced that it has received $25 million in funding from New York City Economic Development Corporation, Third Kind Venture Capital, Red Cell Management, LLC, Bristol-Myers Squibb Company	04.06.
Bristol-Myers Squibb Says Breyanzi Studies Show 'Meaningful' Outcomes Across B-cell Malignancies	03.06.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Schlagzeilen

Bristol-Myers CEO sagt, das Unternehmen sei im Umbruch

Am 09. Januar 2024 um 19:06 Uhr